

May 26, 2025

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
---	---

Dear Sir / Madam,

Sub: Update on safety incident of April 27, 2025 at Lyfius Pharma Private Limited (a wholly owned stepdown subsidiary of the Company) – Reg.,

Ref: Our intimation letter dated April 28, 2025.

With reference to our above-mentioned letter dated April 28, 2025 regarding the safety incident on April 27, 2025, at Lyfius Pharma Private Limited, a wholly owned stepdown subsidiary of the Company (Lyfius), we would like to give the following update:

1. preliminary assessment of loss is estimated around Rs. 40 million and Lyfius is in the process of submitting its final claim with the insurance company.
2. Further, the renewal application for ‘consent to operate’ submitted to Andhra Pradesh Pollution Control Board (APPCB) and their approval is awaited. Lyfius will resume the production once the approval is received from APPCB.

In the event of any further developments on these matters, we will keep the exchanges informed about the same and provide necessary disclosures.

Please take the information on record.

Yours faithfully,

For AUROBINDO PHARMA LIMITED

B. Adi Reddy
Company Secretary

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihaar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com